- Home
- OPHC vs FBIO Comparison
OPHC vs FBIO Comparison
Compare OPHC & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPHC | FBIO |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | United States |
| Employees | N/A | 78 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.0M | 78.3M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | OPHC | FBIO |
|---|---|---|
| Price | $5.46 | $2.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.50 | ★ $17.00 |
| AVG Volume (30 Days) | 42.3K | ★ 259.5K |
| Earning Date | 04-24-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17,095.98 | $55.22 |
| Revenue Next Year | N/A | $40.55 |
| P/E Ratio | $7.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.91 | $1.66 |
| 52 Week High | $5.64 | $4.53 |
Technical Indicators
Market Signals| Indicator | OPHC | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.40 | 40.00 |
| Support Level | $5.20 | $2.20 |
| Resistance Level | $5.51 | $2.49 |
| Average True Range (ATR) | 0.13 | 0.10 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 48.39 | 17.57 |
Price Performance
Historical ComparisonAbout OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. The services provided by the bank include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, borrowings, repayment of loans, money market deposit accounts, debit cards, automated teller machines, and other bank related services.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.